Live price temporarily unavailable.
Price history
Ligand Pharmaceuticals Inc (LGND) is a Health Care company in the Russell 2000. Latest news and coverage below.
About Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
Recent News (3)
-
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
-
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
-
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale
More Health Care stocks
- AZN AstraZeneca
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- AMGN Amgen
- BAX Baxter International